Polymarket is in discussions to raise $400 million at a $15 billion valuation, according to reports. This valuation would position it below competitor Kalshi, which recently achieved a $22 billion valuation in its latest funding round. The deal is part of Polymarket’s efforts to expand its Web3 prediction market platform as of April 2026.
Pakistan and Iran are engaging in talks in Islamabad amid ongoing US-Iran tensions, with Pakistan potentially acting as a regional mediator. While this development could influence diplomatic relations, market sentiment remains cautious due to ongoing uncertainties. The discussions highlight regional efforts to address tensions, but no specific agreements or dates have been disclosed.
Israeli drone flights over Beirut on April 20, 2026, tested Lebanon's ceasefire stability, highlighting regional tensions. The flights raise concerns about the fragile peace and could impact market confidence and geopolitical stability in the Middle East. The incident underscores ongoing security challenges in the region, with potential implications for regional and global markets.
Polymarket is in talks to raise $400 million, valuing the platform at approximately $15 billion. The prediction market, once a niche crypto sector, is now gaining significant attention from Wall Street. The fundraising discussions highlight the growing mainstream interest and potential expansion of Web3 prediction markets as of April 2026.
Crypto funds attracted $1.4 billion in the third consecutive week of inflows, the strongest since January. This sustained investment indicates renewed investor confidence, which could help stabilize market volatility and promote broader adoption of digital assets. The consistent inflows highlight a positive trend in the Web3 sector as of April 2026.
Iran plans to send a delegation for a second round of talks in Islamabad, signaling ongoing diplomatic efforts. The discussions, aimed at improving relations, could influence geopolitical stability and market sentiment. The dates for the talks have not been specified, but the move indicates Iran's continued engagement in diplomatic negotiations.
Merck's stock rose 3% after the FDA granted priority review for two supplemental applications for KEYTRUDA and KEYTRUDA QLEX, combined with Padcev, targeting muscle-invasive bladder cancer. The FDA's target action date is August 17, 2026. The review is based on data from the Phase 3 KEYNOTE-B15 trial, potentially accelerating treatment options for eligible patients.
